These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37844653)

  • 1. IUPHAR themed review: Opioid efficacy, bias, and selectivity.
    Ramos-Gonzalez N; Paul B; Majumdar S
    Pharmacol Res; 2023 Nov; 197():106961. PubMed ID: 37844653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.
    French AR; van Rijn RM
    Pharmacol Res; 2022 Mar; 177():106091. PubMed ID: 35101565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
    Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?
    Madariaga-Mazón A; Marmolejo-Valencia AF; Li Y; Toll L; Houghten RA; Martinez-Mayorga K
    Drug Discov Today; 2017 Nov; 22(11):1719-1729. PubMed ID: 28743488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.
    Schmidhammer H; Erli F; Guerrieri E; Spetea M
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33147885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.
    Burford NT; Traynor JR; Alt A
    Br J Pharmacol; 2015 Jan; 172(2):277-86. PubMed ID: 24460691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid signaling and design of analgesics.
    Paul B; Sribhashyam S; Majumdar S
    Prog Mol Biol Transl Sci; 2023; 195():153-176. PubMed ID: 36707153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Quest for More Effective Analgesics with Reduced Abuse Liability and Fewer Adverse Effects: Promises, Pitfalls, and Future Perspectives of Biased Agonists at Opioid Receptors.
    Bedini A
    Methods Mol Biol; 2021; 2201():181-192. PubMed ID: 32975799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies towards safer opioid analgesics-A review of old and upcoming targets.
    Varga BR; Streicher JM; Majumdar S
    Br J Pharmacol; 2023 Apr; 180(7):975-993. PubMed ID: 34826881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019-2022).
    He Y; Su Q; Zhao L; Zhang L; Yu L; Shi J
    Bioorg Chem; 2023 Dec; 141():106869. PubMed ID: 37797454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noribogaine is a G-protein biased κ-opioid receptor agonist.
    Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
    Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders.
    Pagare PP; Flammia R; Zhang Y
    Pharmacol Res; 2024 Jan; 199():107023. PubMed ID: 38081336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel GPCR paradigms at the μ-opioid receptor.
    Thompson GL; Kelly E; Christopoulos A; Canals M
    Br J Pharmacol; 2015 Jan; 172(2):287-96. PubMed ID: 24460711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics.
    Rehrauer KJ; Cunningham CW
    Pharmacol Res; 2023 Nov; 197():106966. PubMed ID: 37865129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biased ligands at opioid receptors: Current status and future directions.
    Che T; Dwivedi-Agnihotri H; Shukla AK; Roth BL
    Sci Signal; 2021 Apr; 14(677):. PubMed ID: 33824179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.
    Burford NT; Clark MJ; Wehrman TS; Gerritz SW; Banks M; O'Connell J; Traynor JR; Alt A
    Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10830-5. PubMed ID: 23754417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Intracellular Signaling Activities of κ-Opioid Receptor Agonists, Nalfurafine Analogs; Focusing on the Selectivity of G-Protein- and β-Arrestin-Mediated Pathways.
    Yamaguchi M; Miyano K; Hirayama S; Karasawa Y; Ohshima K; Uezono E; Komatsu A; Nonaka M; Fujii H; Yamaguchi K; Iseki M; Hayashida M; Uezono Y
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects.
    Kandasamy R; Hillhouse TM; Livingston KE; Kochan KE; Meurice C; Eans SO; Li MH; White AD; Roques BP; McLaughlin JP; Ingram SL; Burford NT; Alt A; Traynor JR
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for transduction of mu but not kappa opioid modulation of extracellular signal-regulated kinase activity by G(z) and G(12) proteins.
    Belcheva MM; Wong YH; Coscia CJ
    Cell Signal; 2000 Jul; 12(7):481-9. PubMed ID: 10989284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.